DUAL SPECIFICITY PROTEIN KINASE TTK INHIBITOR MARKET ANALYSIS

Market Challenges And Opportunities

Restraints & Challenges:

• Limited access to advanced medical treatments in low-income countries

Limited access to advanced medical treatments in low-income countries: According to the WHO report of 2020, at least half of the world’s population cannot obtain essential healthcare services. Each year, a large number of households are being pushed into poverty because they must pay for healthcare out of their own pockets. Currently, 800 million people spend at least 10 percent of their household budgets on health expenses for themselves, a sick child, or another family member. For almost 100 million people, these expenses are high enough to push them into extreme poverty, forcing them to survive on just $1.90 or less a day. There are wide gaps in the availability of services in sub-Saharan Africa and southern Asia. In other regions, basic health care services such as family planning and infant immunization are becoming more available, but a lack of financial protection means increasing financial distress for families as they pay for these services out of their own pockets.

Global Dual Specificity Protein Kinase Ttk Inhibitor Market– Drivers

Increasing prevalence of cancer is expected to drive the market growth during the forecast period: The increasing prevalence of different types of cancers, such as solid tumor, breast cancer, metastatic breast cancer, colorectal cancer, solid tumor, prostate cancer, pancreatic ductal adenocarcinoma, and others, is expected to drive the global dual specificity protein kinase Ttk inhibitor market growth over the forecast period. For instance, in 2020, according to the America Association of Cancer, approximately 1,414,259 people were diagnosed with prostate cancer.

Increasing number of pipeline molecules of dual specificity protein kinase Ttk inhibitor: The increasing number of pipeline molecules of dual specificity protein kinase Ttk inhibitor as targeted therapies for various types of cancer such as breast cancer, and others, which is expected to propel the global dual specificity protein kinase Ttk inhibitor market growth over the forecast period. For instance, on January 11, 2023, the U.S. Food and Drug Administration (U.S. FDA) granted a fast-track designation to threonine tyrosine kinase (Ttk) inhibitor CFI-402257 for monotherapy, which is used in combination with fulvestrant (Faslodex), for the treatment of adult patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.